Medidata Solutions (MDSO) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS
Medidata Solutions (NASDAQ:MDSO) issued its quarterly earnings results on Tuesday. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.08, MarketWatch Earnings reports. Medidata Solutions had a return on equity of 10.70% and a net margin of 8.43%. The firm had revenue of $167.19 million during the quarter, compared to analysts’ expectations of $168.08 million. During the same period in the previous year, the business earned $0.41 earnings per share. The firm’s revenue for the quarter was up 18.1% on a year-over-year basis. Medidata Solutions updated its FY 2019 guidance to $1.71-1.82 EPS.
Shares of NASDAQ:MDSO opened at $74.23 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.52 and a quick ratio of 2.52. The firm has a market capitalization of $4.48 billion, a price-to-earnings ratio of 87.33, a P/E/G ratio of 4.23 and a beta of 1.32. Medidata Solutions has a 52-week low of $60.10 and a 52-week high of $88.87.
Several analysts recently commented on MDSO shares. BidaskClub cut Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Monday, January 7th. Piper Jaffray Companies dropped their price target on Medidata Solutions from $96.00 to $93.00 in a research report on Thursday, October 18th. Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, December 19th. Finally, ValuEngine upgraded Medidata Solutions from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $83.73.
A number of large investors have recently modified their holdings of MDSO. BlackRock Inc. lifted its stake in shares of Medidata Solutions by 2.9% in the 4th quarter. BlackRock Inc. now owns 6,995,601 shares of the company’s stock valued at $471,644,000 after purchasing an additional 195,763 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Medidata Solutions by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,200,744 shares of the company’s stock valued at $381,266,000 after purchasing an additional 142,687 shares during the last quarter. Vanguard Group Inc lifted its stake in shares of Medidata Solutions by 2.8% in the 3rd quarter. Vanguard Group Inc now owns 5,200,744 shares of the company’s stock valued at $381,266,000 after purchasing an additional 142,687 shares during the last quarter. Clearbridge Investments LLC lifted its stake in shares of Medidata Solutions by 5.9% in the 3rd quarter. Clearbridge Investments LLC now owns 2,429,627 shares of the company’s stock valued at $178,116,000 after purchasing an additional 135,078 shares during the last quarter. Finally, Pictet Asset Management Ltd. lifted its stake in shares of Medidata Solutions by 7.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,626,688 shares of the company’s stock valued at $119,252,000 after purchasing an additional 115,641 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2019/02/12/medidata-solutions-mdso-posts-quarterly-earnings-results-beats-expectations-by-0-08-eps.html.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Featured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.